{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T05:07:39Z","timestamp":1648616859689},"reference-count":36,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2015]]},"DOI":"10.1536\/ihj.14-179","type":"journal-article","created":{"date-parts":[[2014,12,24]],"date-time":"2014-12-24T07:39:11Z","timestamp":1419406751000},"page":"73-79","source":"Crossref","is-referenced-by-count":3,"title":["Plasma Neutrophil Gelatinase-Associated Lipocalin and Worsening Renal Function During Everolimus Therapy After Heart Transplantation"],"prefix":"10.1536","volume":"56","author":[{"given":"Teruhiko","family":"Imamura","sequence":"first","affiliation":[{"name":"Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"Kinugawa","sequence":"additional","affiliation":[{"name":"Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kent","family":"Doi","sequence":"additional","affiliation":[{"name":"Department of Emergency and Critical Care Medicine, Graduate School of Medicine, University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Hatano","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeo","family":"Fujino","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Kinoshita","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Graduate School of Medicine, University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kan","family":"Nawata","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Graduate School of Medicine, University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eisei","family":"Noiri","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Endocrinology, Graduate School of Medicine, University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunei","family":"Kyo","sequence":"additional","affiliation":[{"name":"Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minoru","family":"Ono","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Graduate School of Medicine, University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Lund LH, Edwards LB, Kucheryavaya AY, <i>et al<\/i>. The Registry of the International Society for Heart and Lung Transplantation: Thirtieth Official Adult Heart Transplant Report--2013; focus theme: age. J Heart Lung Transplant 2013; 32: 951-64.","DOI":"10.1016\/j.healun.2013.08.006"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Issa N, Kukla A, Ibrahim HN. Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence. Am J Nephrol 2013; 37: 602-12. (Review)","DOI":"10.1159\/000351648"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Zuckermann A, Manito N, Epailly E, <i>et al<\/i>. Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation. J Heart Lung Transplant 2008; 27: 141-9. (Review)","DOI":"10.1016\/j.healun.2007.08.014"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Gullestad L, Iversen M, Mortensen SA, <i>et al<\/i>. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial. Transplantation 2010; 89: 864-72.","DOI":"10.1097\/TP.0b013e3181cbac2d"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Stypmann J, Engelen MA, Eckernkemper S, <i>et al<\/i>. Calcineurin inhibitor-free immunosuppression using everolimus (Certican) after heart transplantation: 2 years\u2019 follow-up from the University Hospital M\u00fcnster. Transplant Proc 2011; 43: 1847-52.","DOI":"10.1016\/j.transproceed.2010.12.062"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Gude E, Gullestad L, Arora S, <i>et al<\/i>. Benefit of early conversion from CNI-based to everolimus-based immunosuppression in heart transplantation. J Heart Lung Transplant 2010; 29: 641-7.","DOI":"10.1016\/j.healun.2010.01.005"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Budde K, Becker T, Arns W, <i>et al<\/i>. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 2011; 377: 837-47.","DOI":"10.1016\/S0140-6736(10)62318-5"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Imamura T, Kinugawa K, Ono M, <i>et al<\/i>. Everolimus-incorporated immunosuppressant strategy improves renal dysfunction while maintaining low rejection rates after heart transplantation in Japanese patients. Int Heart J 2013; 54: 222-7.","DOI":"10.1536\/ihj.54.222"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Ishida J, Kinugawa K, Shiga T, <i>et al<\/i>. Rapidly progressive caardiac allograft vasculopathy in early onset regressed with everolimus treatment in an adult cardiac recipient. Int Heart J 2012; 53: 388-90.","DOI":"10.1536\/ihj.53.388"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Imamura T, Shiga T, Kinugawa K, <i>et al<\/i>. Successful conversion to everolimus after cytomegalovirus infection in a heart transplant recipient. Int Heart J 2012; 53: 199-201.","DOI":"10.1536\/ihj.53.199"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Ross H, Pflugfelder P, Haddad H, <i>et al<\/i>. Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients. J Heart Lung Transplant 2008; 27: 197-202.","DOI":"10.1016\/j.healun.2007.11.565"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Eisen HJ, Kobashigawa J, Starling RC, <i>et al<\/i>. Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial. Am J Transplant 2013; 13: 1203-16.","DOI":"10.1111\/ajt.12181"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Potena L, Prestinenzi P, Bianchi IG, <i>et al<\/i>. Cyclosporine lowering with everolimus versus mycophenolate mofetil in heart transplant recipients: long-term follow-up of the SHIRAKISS randomized, prospective study. J Heart Lung Transplant 2012; 31: 565-70.","DOI":"10.1016\/j.healun.2012.01.002"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Engelen MA, Welp HA, Gunia S, <i>et al<\/i>. Prospective study of everolimus with calcineurin inhibitor-free immunosuppression after heart transplantation: results at four years. Ann Thorac Surg 2014; 97: 888-93.","DOI":"10.1016\/j.athoracsur.2013.09.031"},{"key":"15","unstructured":"15. Gonzalez-Vilchez F, Vazquez de Prada JA, Paniagua MJ, <i>et al<\/i>. Use of mTOR inhibitors in chronic heart transplant recipients with renal failure: Calcineurin-inhibitors conversion or minimization? Int J Cardiol 2014; 171: 15-23."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Tedesco Silva H Jr, Cibrik D, Johnston T, <i>et al<\/i>. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant 2010; 10: 1401-13.","DOI":"10.1111\/j.1600-6143.2010.03129.x"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Ronco C, Cruz D, Noland BW. Neutrophil gelatinase-associated lipocalin curve and neutrophil gelatinase-associated lipocalin extended-range assay: a new biomarker approach in the early diagnosis of acute kidney injury and cardio-renal syndrome. Semin Nephrol 2012; 32: 121-8.","DOI":"10.1016\/j.semnephrol.2011.11.015"},{"key":"18","unstructured":"18. National Kidney Foundation. K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-266."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Diekmann F, Budde K, Oppenheimer F, Fritsche L, Neumayer HH, Campistol JM. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004; 4: 1869-75.","DOI":"10.1111\/j.1600-6143.2004.00590.x"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Mori K, Nakao K. Neutrophil gelatinase-associated lipocalin as the real-time indicator of active kidney damage. Kidney Int 2007; 71: 967-70. (Review)","DOI":"10.1038\/sj.ki.5002165"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Grgic I, Campanholle G, Bijol V, <i>et al<\/i>. Targeted proximal tubule injury triggers interstitial fibrosis and glomerulosclerosis. Kidney Int 2012; 82: 172-83.","DOI":"10.1038\/ki.2012.20"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Bolignano D, Lacquaniti A, Coppolino G, <i>et al<\/i>. Neutrophil gelatinase-associated lipocalin as an early biomarker of nephropathy in diabetic patients. Kidney Blood Press Res 2009; 32: 91-8.","DOI":"10.1159\/000209379"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Malyszko J, Malyszko JS, Bachorzewska-Gajewska H, Poniatowski B, Dobrzycki S, Mysliwiec M. Neutrophil gelatinase-associated lipocalin is a new and sensitive marker of kidney function in chronic kidney disease patients and renal allograft recipients. Transplant Proc 2009; 41: 158-61.","DOI":"10.1016\/j.transproceed.2008.10.088"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Mishra J, Dent C, Tarabishi R, <i>et al<\/i>. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005; 365: 1231-8.","DOI":"10.1016\/S0140-6736(05)74811-X"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Shen SJ, Hu ZX, Li QH, <i>et al<\/i>. Implications of the changes in serum neutrophil gelatinase-associated lipocalin and cystatin C in patients with chronic kidney disease. Nephrology (Carlton) 2014; 19: 129-35.","DOI":"10.1111\/nep.12203"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Doi K, Urata M, Katagiri D, <i>et al<\/i>. Plasma neutrophil gelatinase-associated lipocalin in acute kidney injury superimposed on chronic kidney disease after cardiac surgery: a multicenter prospective study. Crit Care 2013; 17: R270.","DOI":"10.1186\/cc13104"},{"key":"27","unstructured":"27. Vernuccio F, Grutta G, Ferrara F, Novo G, Novo S. Cardiorenal syndrome: the role of new biochemical markers. Recenti Prog Med 2012; 103: 559-63. (Italian)"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Yang J, Goetz D, Li JY, <i>et al<\/i>. An iron delivery pathway mediated by a lipocalin. Mol Cell 2002; 10: 1045-56.","DOI":"10.1016\/S1097-2765(02)00710-4"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Przybylowski P, Malyszko J, Malyszko JS. Serum neutrophil gelatinase-associated lipocalin correlates with kidney function in heart allograft recipients. Transplant Proc 2010; 42: 1797-802.","DOI":"10.1016\/j.transproceed.2010.02.079"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Singer E, Mark\u00f3 L, Paragas N, <i>et al<\/i>. Neutrophil gelatinase-associated lipocalin: pathophysiology and clinical applications. Acta Physiol (Oxf) 2013; 207: 663-72. (Review)","DOI":"10.1111\/apha.12054"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Ponticelli C, Graziani G. Proteinuria after kidney transplantation. Transpl Int 2012; 25: 909-17. (Review)","DOI":"10.1111\/j.1432-2277.2012.01500.x"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Diekmann F, Andr\u00e9s A, Oppenheimer F. mTOR inhibitor-associated proteinuria in kidney transplant recipients. Transplant Rev (Orlando) 2012; 26: 27-9. (Review)","DOI":"10.1016\/j.trre.2011.10.003"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Roodnat JI, Mulder PG, Rischen-Vos J, <i>et al<\/i>. Proteinuria after renal transplantation affects not only graft survival but also patient survival. Transplantation 2001; 72: 438-44.","DOI":"10.1097\/00007890-200108150-00014"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Uchida J, Machida Y, Iwai T, <i>et al<\/i>. Low-grade albuminuria reduction with angiotensin II type 1 receptor blocker in renal transplant recipients. J Nephrol 2011; 24: 515-21.","DOI":"10.5301\/JN.2011.6235"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Blacklock CL, Hirst JA, Taylor KS, Stevens RJ, Roberts NW, Farmer AJ. Evidence for a dose effect of renin-angiotensin system inhibition on progression of microalbuminuria in Type 2 diabetes: a meta-analysis. Diabet Med 2011; 28: 1182-7.","DOI":"10.1111\/j.1464-5491.2011.03341.x"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Gonz\u00e1lez-Vilchez F, de Prada JA, Castrillo C, Canteli A, Llano MF, Mart\u00edn-Dur\u00e1n R. Predictors of long-term renal function after conversion to proliferation signal inhibitors in long-term heart transplant recipients. J Heart Lung Transplant 2011; 30: 552-7.","DOI":"10.1016\/j.healun.2010.11.005"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","deposited":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T00:00:13Z","timestamp":1566172813000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/56\/1\/56_14-179\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.14-179","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}